FEUGIER, P. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma : a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005, 23, 4117-4126
PFREUNDSCHUH, M. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma : a randomised controlled trial by the Mab-Thera International Trial (MInT) Group. Lancet Oncol. 2006, 7, 379-391
SEHN, LH. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007, 109, 1857-1861
HIDDEMANN, W. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone : results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005, 106, 3725-3732